lunes, 22 de abril de 2024
Microbiome-based therapeutics Published: April 8, 2024
https://www.thelancet.com/series/Microbiome-based-therapeutics
The gut microbiome plays an important part in a number of gastrointestinal conditions, including Clostridioides difficile infection and inflammatory bowel disease. Interest in modulating the gut microbiome, through prebiotics, probiotics, and natural or artificial microbiota therapeutics, has increased markedly in the past decade. Although the field has developed rapidly, it has faced reproducibility issues and encountered safety and regulatory hurdles. This two-part Series explores the development and promise of artificial microbiome therapeutics, and the current and future perspectives for microbiota therapies for treating inflammatory bowel disease.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario